Search
Close this search box.

Najat Khan leaving J&J for Recursion

ARTICLE | Management Tracks

Plus: Innovent hires Nageatte Ibrahim as oncology CMO, and updates from Endeavor and Vittoria

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst  

April 17, 2024 12:06 AM UTC

Najat Khan will depart as chief data science officer and global head of strategy, portfolio and operations for R&D at the Johnson & Johnson Innovative Medicine unit of Johnson & Johnson (NYSE:JNJ) to become chief R&D officer, chief commercial officer and a board member at Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Recursion is a techbio drug discovery company that uses its phenotypic screening platform to predict targets. Khan was a guest on The BioCentury Show last year.

Innovent Biologics Inc. (HKEX:1801) hired Nageatte Ibrahim as oncology CMO. Ibrahim was VP, global clinical development, oncology at Merck & Co. Inc. (NYSE:MRK), where she held roles for nearly a decade…